NICE Throws AZ's Lynparza A Bone
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, may decide after all to recommend AstraZeneca's PARP inhibitor Lynparza (olaparib) as a maintenance treatment for a subset of NHS patients with maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer. If it sees the right evidence, it says it may be able to use flexibilities to consider more expensive treatments.